Today: 7 February 2026
Subscribe
Browse Category

NYSE:BMY News 10 October 2025 - 20 December 2025

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
········
Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts that could shape the post–patent-cliff narrative. As of 2:00 p.m. (quotes delayed), BMY shares were $53.66, down 1.15% on the session, with a 52‑week range of $42.52 to $63.33. Bristol Myers Squibb BMY stock today: Where shares are trading and what that implies The mid‑$50s trading zone matters because it has become the market’s “battleground price” between two competing views:
16 December 2025
·
Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a steady drumbeat of pipeline and regulatory updates heading into 2026. Smartkarma While BMY has spent much of the past year wrestling with familiar big-pharma headwinds—generic erosion in legacy products and a looming “patent cliff” narrative—the last several weeks have looked more like a sentiment reset than a victory lap. One analysis notes a ~16% move over the last 30 days
16 December 2025
···
Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is ending Monday’s session in the spotlight after a sharp, analyst-driven move that pushed the pharma giant higher into the close — and kept the shares firm in extended trading. After the closing bell on Monday, December 15, 2025, BMY was up about 3.6% in regular trading and added roughly another 0.6% after hours, as investors digested a bullish call from Bank of America and looked ahead to a potentially volatile macro catalyst before Tuesday’s open. MarketWatch Below is what moved the stock, what analysts are forecasting now, and the key items worth watching before
16 December 2025
··
Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Bristol-Myers Squibb Stock (BMY) News, Forecasts and Analysis for Dec. 12, 2025: Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus

Dec. 12, 2025 — Bristol-Myers Squibb Company (NYSE: BMY ) is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and frustrating setbacks in 2025. By mid-day Friday, BMY stock traded around $52.50, up roughly 2.5% , reflecting a market that’s starting to re-price near-term catalysts even as longer-term questions—patent cliffs, trial readouts, and litigation—remain front and center. BMY stock price today: what’s moving the shares on Dec. 12 The most immediate “today” driver is Wall Street sentiment . On Friday,
12 December 2025
·
Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (NYSE: BMY) has packed a lot into the first week of December 2025 – from a surprise update on a key Alzheimer’s drug trial to major hematology data at ASH 2025 and a legal setback over its Celgene acquisition. All of this is landing on a stock that has finally bounced after years of underperformance but still trades as a high‑yield value name. As of the market close on Friday, 5 December 2025, BMY shares were at $52.15, with after‑hours trading around $52.05, giving the company a market capitalization of roughly $106 billion. The stock’s 52‑week range
7 December 2025
·
Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

As of December 4, 2025, Bristol Myers Squibb Company (NYSE: BMY) is back on the radar of growth, value and dividend investors. After a sharp rally this week driven by fresh news on its Alzheimer’s drug Cobenfy, an AI-enabled drug discovery milestone and a high‑stakes lawsuit ruling, BMY stock is trading around $50.55, giving the U.S. pharma giant a market capitalization of roughly $104 billion.MarketBeat At the same time, investors are weighing a near‑5% dividend yield, looming patent cliffs for Eliquis and Opdivo, and a newly revived $6.7 billion Celgene CVR lawsuit.Business Wire+2Reuters+2 This article rounds up the latest Bristol
4 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples, these cross-currents are shaping how investors see BMY stock heading into 2026. BMY Stock Snapshot on 2 December 2025 On a day when the S&P 500 rose 0.25% and the Dow gained 0.39%, BMY underperformed peers: Johnson & Johnson ticked up slightly, while Pfizer and Abbott fell less than Bristol-Myers. MarketWatch For investors watching Google News and Discover, the headline
3 December 2025
··
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH 2025 is impressive, and investors are reassessing the stock’s value, dividend and medium‑term growth story. Below is a deep dive into today’s key news, current price, latest forecasts and what it all might mean for BMY stock. This article is for information only and is not investment advice. BMY Stock Snapshot on 1 December 2025 In other words: BMY is
2 December 2025
·
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight today after the company and its partner Johnson & Johnson announced they will discontinue a major Phase 3 trial of their experimental blood thinner milvexian in acute coronary syndrome (ACS). The decision, based on a scheduled interim review showing the study was unlikely to hit its main goal, has pushed BMY shares lower and reignited
14 November 2025
···
Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

Bristol Myers Squibb (NYSE:BMY) Surges on Q3 Earnings Beat and Raised Outlook – What’s Next for BMY Stock?

BMY Stock Bounces After Earnings – Recent Performance Bristol Myers Squibb’s stock has been under pressure for most of 2025, but the Q3 report provided a much-needed boost. Heading into earnings, BMY shares were near 52-week lows, reflecting investor skittishness over looming patent cliffs and mixed news in prior quarters. In fact, on October 28, the stock touched a one-year low of $42.96 (closing at $42.99) Marketbeat. That put BMY down roughly 18–19% year-to-date, significantly underperforming the pharma sector (which was roughly flat to slightly up over the same period) Nasdaq. By comparison, an index of large pharmaceutical stocks was
30 October 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 15.10.2025

BMY shines under Partha Mohanram’s P/B Growth model with an 88% rating October 15, 2025, 11:18 PM EDT. Validea’s guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring highest under Partha Mohanram’s P/B Growth Investor model, a framework targeting low book-to-market names with signs of sustained growth. BMY, a large-cap growth stock in the Biotechnology & Drugs industry, earns an 88% rating, signaling notable interest from this strategy (scores above 90% show strong interest; around 80% signals some interest). Most tests come back PASS across the framework-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS,
15 October 2025
·
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery Bms Fiercebiotech. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ Bms Orbitaltx. This approach could
10 October 2025
·
1 2

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop